SCHEMBL3055313

SCHEMBL3055313

[CH2]c1ccc(OCC(F)F)c(OC)c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.43
MAPT P10636 3/20 0.43
LMNA P02545 2/20 0.43
SMN1; SMN2 Q16637 2/20 0.43
KDM4E B2RXH2 2/20 0.43
GAA P10253 2/20 0.43
MEN1 O00255 2/20 0.43
KMT2A Q03164 2/20 0.43
HTT P42858 1/20 0.43
AGTR1 P30556 1/20 0.40
CYP1A2 P05177 1/20 0.40
TSHR P16473 3/20 0.38
NPC1 O15118 1/20 0.38
TP53 P04637 1/20 0.38
RAB9A P51151 1/20 0.38
HIF1A Q16665 2/20 0.37
EPAS1 Q99814 2/20 0.37
FDPS P14324 2/20 0.37
CA2 P00918 2/20 0.36
PPARG P37231 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4436990 0.84 ALDH1A1 (0.50) ALDH1A1MAPTLMNASMN1; SMN2KDM4E
SCHEMBL28080918 0.81 ACHE (0.59) ALDH1A1MAPTLMNASMN1; SMN2KDM4E
SCHEMBL20681622 0.79 KDM4E (0.62) ALDH1A1MAPTLMNASMN1; SMN2KDM4E
SCHEMBL356412 0.78 KDM4E (0.59) ALDH1A1MAPTSMN1; SMN2KDM4EGAA
SCHEMBL8202942 0.77 ALDH1A1 (0.50) ALDH1A1MAPTLMNASMN1; SMN2KDM4E
SCHEMBL2713576 0.77 NPC1 (0.52) ALDH1A1MAPTLMNASMN1; SMN2KDM4E
SCHEMBL2714767 0.77 TTR (0.53) ALDH1A1MAPTLMNASMN1; SMN2KDM4E
SCHEMBL4550723 0.77 KDM4E (0.49) ALDH1A1MAPTLMNASMN1; SMN2KDM4E
SCHEMBL27090 0.77 CA2 (0.54) ALDH1A1KDM4EGAACYP1A2TSHR
SCHEMBL16954400 0.77 PDE4B (0.46) ALDH1A1MAPTLMNASMN1; SMN2KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8551999-B2 Heterocyclic compound and pharmaceutical composition thereof OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-10-08 US disclosed
EP-2207773-B1 HETEROCYCLIC COMPOUND AND PHARMACEUTICAL COMPOSITION THEREOF OTSUKA PHARMA CO LTD (JP) 2012-07-11 EP disclosed
US-20100261720-A1 HETEROCYCLIC COMPOUND AND PHARMACEUTICAL COMPOSITION THEREOF OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2010-10-14 US disclosed
EP-2207773-A2 HETEROCYCLIC COMPOUND AND PHARMACEUTICAL COMPOSITION THEREOF Otsuka Pharmaceutical Co., Ltd. (JP) 2010-07-21 EP disclosed
WO-2009057811-A2 HETEROCYCLIC COMPOUND AND PHARMACEUTICAL COMPOSITION THEREOF OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2009-05-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100261720-A1 HETEROCYCLIC COMPOUND AND PHARMACEUTICAL COMPOSITION THEREOF COL1A1, COL2A1, COL14A1 ALDH1A1 741/4885MAPT 4138/4885LMNA 1184/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.